LBP, Mouse, mAb M330-19
Quantity:
100 µg
Catalog #:
HM1026-100UG
The monoclonal antibody M330-19 reacts highly specific with mouse natural and recombinant LBP. The antibody is a type I antibody blocking the LPS binding to LBP. LPS binding protein (LBP) is an approximately 60 kDa acute phase protein that is produced by hepatocytes. This protein strongly binds to LPS and has been shown to play an important role in the handling of LPS by the host. A number of functions of LBP have been reported. First, LBP transfers LPS to the LPS receptor CD14 on mononuclear phagocytes, leading to an 100-1,000-fold increased sensitivity of the cells to LPS. Furthermore, LBP can enhance the response of CD14 negative cells by acceleration of LPS binding to soluble CD14, a complex that stimulates these cells. Next, LBP transfers LPS into High Density Lipoprotein (HDL), which effectively neutralizes its biological potency. LBP was demonstrated to protect mice from septic shock caused by LPS or gram negative bacteria.
| Product type | Monoclonal antibodies |
|---|---|
| Quantity | 100 µg |
| Formulation | 1 ml (100 µg/ml) 0.2 µm filtered antibody solution in PBS, containing 0.1% bovine serum albumin. |
| Application | Functional studies, Immuno assays |
| Use | Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:10. For neutralization of biological activity dilutions have to be made according to the amounts LBP to be inactivated. |
| Isotype | Rat IgG2a |
| Species | Mouse |
| Cross reactivity | Human - No |
| References | 1.Le Roy, D et al; Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal endotoxemia by blocking either the binding of LPS to LBP or the presentation of LPS/LBP complexes to CD14. J Immunol 1999, 162: 7454 2. Le Roy, D et al; Critical role of lipopolysaccharide-binding protein and CD14 in immune response against gram-negative bacteria. J Immunol 2001, 169: 2759 3. Heumann, D et al; Role of Plasma, Lipopolysaccharide-Binding Protein, and CD14 in Response of Mouse Peritoneal Exudate Macrophages to Endotoxin. Inf and Immun 2001, 69:378 |
| Storage and stability | Product should be stored at 4°C. Under recommended storage conditions, product is stable for one year. |
| Precautions | For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use of or derivation of this product. |
| Disease | Infectious diseases |
| Application: | Functional studies, Immuno assays |
|---|---|
| Application notes: | The antibody can be used for functional studies in vitro and in vivo aimed at blocking LBP. Furthermore the antibody is useful for immuno assays. |
| Use: | Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:10. For neutralization of biological activity dilutions have to be made according to the amounts LBP to be inactivated. |
| References: | 1.Le Roy, D et al; Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal endotoxemia by blocking either the binding of LPS to LBP or the presentation of LPS/LBP complexes to CD14. J Immunol 1999, 162: 7454 2. Le Roy, D et al; Critical role of lipopolysaccharide-binding protein and CD14 in immune response against gram-negative bacteria. J Immunol 2001, 169: 2759 3. Heumann, D et al; Role of Plasma, Lipopolysaccharide-Binding Protein, and CD14 in Response of Mouse Peritoneal Exudate Macrophages to Endotoxin. Inf and Immun 2001, 69:378 |
|---|
CoA-TDS HM1000-HM1066
Protocol
